Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
New initiative aims to drive forward clinical trial research for MDR TB
At the annual TB Union Conference held in Cape Town in November 2007, a number of actors, concerned by the continuing lack of sufficient research activity to tackle drug-resistant TB, decided to launch a new initiative.
The first fruit was a workshop held in Boston, USA in June 2008 on drug resistant TB that brought together representatives from National Treatment Programmes from countries with high burden MDR TB, NGOs, activist groups, scientists and researchers, pharmaceutical industry and representatives from regulating agencies and funders.
The participants decided to set up a new entity, focusing initially on the development of a proposal to move forward in the conduct of MDR TB clinical trials. The group also issued a manifesto, The Cambridge Declaration, outlining their aims.
These include the conduct of the most important priority trials to test strategies that will shorten and improve treatment for drug-resistant TB. As well, the group takes as its remit to mobilise the resources for these trials and to build the capacity of clinical trial sites.
Find out more about the activities of the DR-TB trials Working-Group
PLoS series on MDR TB clinical trials
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
